Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/9/2026 | $92.00 | Overweight | KeyBanc Capital Markets |
| 6/13/2025 | $69.00 | Buy | B. Riley Securities |
| 3/5/2025 | $85.00 → $65.00 | Outperform → Strong Buy | Raymond James |
| 9/6/2024 | $57.00 → $79.00 | Equal Weight → Overweight | Barclays |
| 3/6/2024 | $48.00 | Equal Weight | Barclays |
| 8/31/2023 | $40.00 | Buy | Truist |
| 3/31/2023 | $30.00 | Market Outperform | CJS Securities |
| 3/3/2023 | $30.00 | Mkt Perform → Outperform | Raymond James |
KeyBanc Capital Markets initiated coverage of RadNet with a rating of Overweight and set a new price target of $92.00
B. Riley Securities initiated coverage of RadNet with a rating of Buy and set a new price target of $69.00
Raymond James upgraded RadNet from Outperform to Strong Buy and set a new price target of $65.00 from $85.00 previously
4 - RadNet, Inc. (0000790526) (Issuer)
4 - RadNet, Inc. (0000790526) (Issuer)
4 - RadNet, Inc. (0000790526) (Issuer)
LOS ANGELES, March 17, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the KeyBanc Capital Markets Healthcare Forum on Tuesday, March 17, 2026 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). There will be simultaneous and archived webcasts available at https://wsw.com/webcast/key40/rdnt/1686072 About RadNet, Inc.RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of
LOS ANGELES, March 11, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the 28th Annual Barclays Global Healthcare Conference on Thursday, March 12, 2026 at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time). There will be simultaneous and archived webcasts available at https://urldefense.com/v3/__https://cc.webcasts.com/barc002/031026a_js/?entity=144_X3VLDEI__;!!COmMWt7_Sw!XlHi2Z0Y8oljWTGFQhCAlqx-WUpj99UPNp1_sposW-TqahO41Keizcqhw9B4eULlXCe9bGpTDgrQlnQ9cI0$ Det
VIENNA, March 04, 2026 (GLOBE NEWSWIRE) -- DeepHealth, a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ:RDNT), today unveils at ECR 2026 the industry's most comprehensive portfolio of native clinical AI solutions and services across all core imaging modalities — MR, CT, X-ray, Mammography and Ultrasound — and spanning detection, assessment and monitoring, all available on one platform. With this week's acquisition of Gleamer, DeepHealth further expands its leadership in advancing screening tools into routine imaging and acute diagnostic care, uniquely positioned to deliver the next era of AI-powered health informatics. "As European na
10-K - RadNet, Inc. (0000790526) (Filer)
8-K - RadNet, Inc. (0000790526) (Filer)
8-K - RadNet, Inc. (0000790526) (Filer)
SC 13G/A - RadNet, Inc. (0000790526) (Subject)
SC 13G/A - RadNet, Inc. (0000790526) (Subject)
SC 13G/A - RadNet, Inc. (0000790526) (Subject)
CERRITOS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Mark Stolper has joined the Board of Directors, effective January 2, 2026. Mr. Stolper brings significant public markets, financial and operational leadership experience to The Oncology Institute's board. Mr. Stolper serves as Executive Vice President and Chief Financial Officer of RadNet, Inc. (NASDAQ:RDNT), a position he has held since 2004. Mr. Stolper has also been a member of the Board of Directors of various publicly traded and privately held healthcare companies, including 21st Century Oncolog
Former Chief Business Leader of Philips' multi-billion-dollar Precision Diagnosis division and member of Philips' Executive CommitteeEnd-to-end responsibility for Philip's CT, MR, dXR, Ultrasound and Diagnostic Informatics (radiology software) businessesProven track record of building and managing radiology software solutions, including significant experience with AI development and commercialization LOS ANGELES, Sept. 12, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers and digital health solutions, announced today the appo
LOS ANGELES, March 04, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, reminds investors that on Thursday, March 5, 2026, investors are invited to join a dedicated conference call and presentation to hear more details about the recently completed acquisition of Gleamer SAS and RadNet's Digital Health strategy. On the call, investors will also have the opportunity to ask questions of executive management. Investor Call Details: The conference call will take place at 7:30 a.m. Pacific Time/10:30 am. Eastern Time/4:30 p.m. Centr
Total Company Revenue increased 14.8% to a quarterly record of $547.7 million in the fourth quarter of 2025 from $477.1 million in the fourth quarter of 2024; Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 48.2% to $27.9 million in the fourth quarter of 2025 from $18.9 million in the fourth quarter of 2024Total Company Adjusted EBITDA(1) was a quarterly record of $87.7 million in the fourth quarter of 2025 as compared with $75.0 million in the fourth quarter of 2024, an increase of 16.9%; Digital Health reportable segment Adjusted EBITDA(1) increased 8.9% to $4.9 million in the fourth quarter of 2025 from $4.5 million in the fourth quarter of
Based in Paris, France, Gleamer serves over 700 customer contracts worldwide with a broad portfolio of FDA-cleared and CE-marked solutions for musculoskeletal, breast, lung and neurologic applications.Gleamer's leadership in routine imaging, and particularly X-ray, is unparalleled through the breadth and scale of its cloud-first AI solutions. DeepHealth, combined with Gleamer's solutions will provide the industry's most comprehensive portfolio of native clinical AI solutions and services across all core imaging modalities. Gleamer achieved an Annual Recurring Revenue ("ARR") i compound annual growth rate exceeding 90% from 2022 through 2025 and is expected to reach approximately $30 millio